{"entity":{"id":"perspective-therapeutics","kind":"company","name":"Perspective Therapeutics","aka":[],"tldr":"Lead-212 alpha-therapy company whose SSTR2 agent [212Pb]VMT-α-NET reported a 43% response rate in neuroendocrine tumours and is heading for phase 3.","summary":"Phase 1/2a of [212Pb]VMT-α-NET (NCT05636618): 43% ORR in cohort 2 with 72% progression-free/alive at the 2026 update; 76 NET patients treated by July 2026; first meningioma patient dosed June 2026; EU orphan designation July 2026. Phase 3 planned at a cumulative 20 mCi dose. Also developing PSMA and melanocortin-1 receptor 212Pb agents. Its FAP-alpha agent PSV359, paired with the 203Pb/68Ga imaging analogue PSV377, is in a phase 1/2 first-in-human study (NCT06710756); on 14 September 2026 the company announced a collaboration and supply agreement with Merck to add cohorts combining [212Pb]PSV359 with pembrolizumab in FAP-alpha-positive non-small cell lung cancer and colorectal cancer, which is the first time an alpha-emitting radioligand has been taken into NSCLC. The dose-expansion part of the VMT-alpha-NET trial also enrols bronchial neuroendocrine tumours.","asOf":"2026-09-04","links":[{"label":"Q2 2026 highlights","url":"https://www.globenewswire.com/news-release/2026/08/10/3342260/0/en/perspective-therapeutics-provides-recent-business-highlights-and-reports-2q-2026-results.html"},{"label":"Clinical collaboration and supply agreement with Merck to evaluate [212Pb]PSV359 with Keytruda in FAP-alpha positive solid tumours, including NSCLC (14 September 2026)","url":"https://www.perspectivetherapeutics.com/pr/perspective-therapeutics-announces-clinical-collaboration-and-supply-agreement-with-merck-to-evaluate-212pbpsv359-in-combination-with-keytruda-pembrolizumab-in-fap-a-positive-solid-tumors"}],"tags":[],"related":["nsclc","lung-net","ga-68","pb-212"],"indications":["neuroendocrine"],"sections":[],"technologies":["targeted-alpha-therapy"],"targets":["sstr2","psma"],"drugs":["pb-212-vmt-alpha-net","pb-212-psv359"],"companies":[],"institutions":[],"pathways":[],"terms":["alpha-vs-beta"],"trials":["nct05655312","nct05636618","nct06710756"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Seattle, WA","country":"US","companyType":"radiopharma","website":"https://perspectivetherapeutics.com","ticker":"CATX","investors":[],"funding":[]},"route":"/companies/perspective-therapeutics/","neighbours":{"indication":[{"id":"lung-net","kind":"indication","name":"Lung neuroendocrine tumours (typical and atypical carcinoid)","route":"/indications/lung-net/"},{"id":"neuroendocrine","kind":"indication","name":"Neuroendocrine tumours","route":"/indications/neuroendocrine/"},{"id":"nsclc","kind":"indication","name":"Non-small cell lung cancer","route":"/indications/nsclc/"}],"isotope":[{"id":"ga-68","kind":"isotope","name":"Gallium-68","route":"/isotopes/ga-68/"},{"id":"pb-212","kind":"isotope","name":"Lead-212","route":"/isotopes/pb-212/"}],"technology":[{"id":"alpha-nanogenerators","kind":"technology","name":"Alpha-emitter nanogenerators and daughter trapping","route":"/technologies/alpha-nanogenerators/"},{"id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/"}],"target":[{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/"},{"id":"sstr2","kind":"target","name":"Somatostatin receptor 2","route":"/targets/sstr2/"}],"drug":[{"id":"pb-212-psv359","kind":"drug","name":"Lead-212 PSV359","route":"/drugs/pb-212-psv359/"},{"id":"pb-212-vmt-alpha-net","kind":"drug","name":"Lead-212 VMT-alpha-NET","route":"/drugs/pb-212-vmt-alpha-net/"}],"term":[{"id":"alpha-vs-beta","kind":"term","name":"Alpha vs beta emitters","route":"/terms/alpha-vs-beta/"}],"trial":[{"id":"nct06710756","kind":"trial","name":"Lead-212 PSV359 Therapy for Patients With Solid Tumors","route":"/trials/nct06710756/"},{"id":"nct05655312","kind":"trial","name":"MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma","route":"/trials/nct05655312/"},{"id":"nct05636618","kind":"trial","name":"Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors","route":"/trials/nct05636618/"}],"idea":[{"id":"idea-reg-alpha-emitter-portfolio","kind":"idea","name":"Fund alpha emitters beyond actinium-225: lead-212, terbium-149 and astatine-211","route":"/ideas/idea-reg-alpha-emitter-portfolio/"}],"section":[{"id":"f-alpha-therapy","kind":"section","name":"Targeted alpha therapy","route":"/fronts/f-alpha-therapy/"}]}}